Study | Reason for exclusion |
---|---|
Albers 2016 | Post‐hoc analysis of observational study |
Alvarez‐Cuesta 1994 | Intervention used in study (cat extract immunotherapy) is not anti‐IL‐5 therapy |
Armentia 1992 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Austin 2016 | Aggregation of two clinical trials |
Ayres 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bel 2014 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
Berger 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Blanken 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Blanken 2013 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
Boulet 1997 | Intervention used in study (anti‐IgE antibody e25) is not anti‐IL‐5 therapy |
Bousquet 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bousquet 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Brightling 2014 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Brown 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Brusselle 2016 | Aggregation of two clinical trials |
Bryant 1975a | Not a RCT |
Bryant 1975b | Not a RCT |
Buhl 2000a | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
Buhl 2000b | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
Buhl 2002 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bush 1985 | Intervention used in study (soybean oil) is not anti‐IL‐5 therapy |
Busse 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Busse 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Busse 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Buttner 2003 | Treatment < 16 weeks |
Caffarelli 2000 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Canvin 2016 | Aggregation of two clinical trials |
Castro 2011 | < 16 weeks in length |
Castro 2014b | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Chandra 1989 | Intervention used in study (various foods) is not anti‐IL‐5 therapy |
Chervinsky 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Clavel 1998 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Corren 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Corren 2010 | Intervention used in study (il‐4ralpha antagonist) is not anti‐IL‐5 therapy |
Cullell‐Young 2002 | Not a RCT |
Dasgupta 2016 | Participants did not have a diagnosis of asthma (COPD patients) |
De Boever 2014 | Intervention used in study (anti‐IL‐13 mab) is not anti‐IL‐5 therapy |
Djukanovic 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Ebner 1989 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Eckman 2010 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
El‐Nawawy 2000 | Not a RCT |
EUCTR2012‐004385‐17‐BE | The study participants did not have asthma |
EUCTR2014‐002666‐76‐GB | Treatment period < 16 weeks |
EUCTR2014‐003162‐25‐DE | The study participants did not have asthma |
EUCTR2015‐001152‐29‐BE | Not an RCT and endpoints are not applicable as this is a long‐term access programme |
EUCTR2015‐003697‐32‐NL | Not placebo‐controlled. Single treatment arm only |
EUCTR2016‐001831‐10‐NL | No placebo arm/single treatment arm and treatment duration < 16 weeks |
EUCTR2016‐002405‐19‐DE | Participants do not have a diagnosis of asthma, no placebo arm, treatment duration < 16 weeks |
Fahy 1997 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Fahy 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Ferrguson 2016 | Treatment duration < 16 weeks in length |
Finn 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Flood‐Page 2003 | Treatment < 16 weeks |
Flood‐Page 2007 | Treatment < 16 weeks |
Frew 1998 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Garcia 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Gauvreau 2011 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
Gauvreau 2014a | Intervention used in study ( anti‐tslp) is not anti‐IL‐5 therapy |
Gauvreau 2014b | Intervention used in study (ox40l antagonism) is not anti‐IL‐5 therapy |
Gauvreau 2014c | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
Gauvreau 2015a | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
Gauvreau 2015b | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
Gevaert 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Gordon 1972 | Intervention used in study is not anti‐IL‐5 therapy |
Greenberg 1991 | Participants do not have a diagnosis of asthma |
Gunsoy 2016 | Not a randomised, placebo‐controlled trial |
Han 2009 | Intervention used in study ( jade screen powder) is not anti‐IL‐5 therapy |
Hanania 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hanania 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hanania 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Hanania 2015 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Harris 2016 | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
Hendeles 2015 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hill 1982 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Hodsman 2013 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
Holgate 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hoshino 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Jacquemin 1995 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Jutel 2005 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Kang 1988 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Kips 2003 | Treatment < 16 weeks |
Kon 2001 | Intervention used in study (anti‐cd4) is not anti‐IL‐5 therapy |
Kopp 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Kopp 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Kulus 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Lanier 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Lanier 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Laviolette 2013 | Treatment < 16 weeks |
Leckie 2000 | Treatment < 16 weeks |
Leynadier 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Li 2016 | Review article, not a RCT |
Lizaso 2008 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Lugogo 2016 | Not a randomised, placebo‐controlled trial |
Maspero 2016 | Combined secondary analysis of two trials: NCT01287039 and NCT01285323 |
Massanari 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Massanari 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Metzger 1998 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Milgrom 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Milgrom 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Modlin 1977 | Participants do not have diagnosis of asthma |
Moss 1987 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Nair 2009 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
Nair 2016 | All participants do not have a diagnosis of asthma |
NCT00783289 2008 | Treatment duration < 16 weeks |
NCT00802438 | Non randomised study |
NCT01290887 2011 | Study does not include a placebo arm |
NCT01366521 | Phase 2 study comparing three doses of mepolizumab. This trial does not have a placebo arm |
NCT01471327 | Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB‐240563 administered intravenously to Japanese healthy male participants. People with asthma were not included in the study. |
NCT01691859 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered subcutaneously (no control group) |
NCT01842607 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered subcutaneously (no control group) |
NCT02075255 2014 | Focus of trial is on oral steroid reduction |
NCT02135692 | This study does not include a placebo group. Multi‐center, open‐label, long‐term study of subcutaneously (SC) administered mepolizumab 100 mg in addition to standard of care (SOC), in participants with severe eosinophilic asthma |
NCT02258542 2014 | Not a RCT (an extension study with no placebo arm) |
NCT02293265 | Aim of study is to provide a 'reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab'. No pharmaceutical intervention in study |
NCT02417961 2015 | Not a RCT |
NCT02501629 2015 | Focus of trial is on oral steroid reduction |
NCT02559791 | Not placebo‐controlled ‐ single treatment arm only |
NCT02808819 2016 | Not a RCT |
NCT02814643 2016 | Treatment duration < 16 weeks |
NCT02869438 | Treatment duration < 16 weeks |
NCT02937168 | Treatment duration < 16 weeks |
NCT02968914 | Not a placebo‐controlled trial |
NCT03014674 | Not a placebo‐controlled trial and treatment duration < 16 weeks |
NCT03021304 | No placebo arm/single treatment arm, treatment duration < 16 weeks |
Newbold 2016 | Not a RCT |
Niven 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noga 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noga 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noonan 2013 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Nowak 2015 | Treatment < 16 weeks |
Oba 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Oh 2013 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
Ohashi 1997 | Participants do not have a diagnosis of asthma |
Ohman 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Ohta 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Ong 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Park 1998 | Not a RCT |
Parker 2010 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
Pauli 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Pavord 2012b | Posthoc analysis of Pavord 2012a and Ortega 2014 stratified by prior use of anti‐IgE therapy |
Pelaia 2016 | Study is not a RCT |
Pham 2016 | An analysis of sera collected from asthma patients enrolled in two clinical studies: NCT00659659 and NCT00783289 |
Piper 2012 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Piper 2013 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Pouliquen 2015 | Study has no placebo arm or clinical endpoints |
Pouliquen 2016 | Aggregation of two clinical trials |
Prazma 2016 | Study is not a randomised, placebo controlled trial |
Prieto 2006 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Pui 2010 | Intervention used in study (air/diesel exhaust +/‐ antioxidant) is not anti‐IL‐5 therapy |
Ranade 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Rose 2009 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
Sakamoto 1984 | Not a RCT |
Scheerens 2011 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Scheerens 2012 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Scheerens 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Siergiejko 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Silk 1998 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
Silkoff 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Simoes 2007 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
Singh 2010 | Intervention used in study (anti‐IL‐13) is not anti‐IL‐5 therapy |
Slavin 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Soler 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Sorkness 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Sthoeger 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Sugaya 1994 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
Swanson 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Szymaniak 1998 | Not a RCT |
Tanaka 1993 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
Terr 1969 | Study predates monoclonal treatments |
Van Rensen 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Vignola 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Virchow 2016 | Aggregation of two clinical trials |
Wang 2015 | Pharmacometrics assessment of phase IIb data to characterize the exposure‐response relationship with Benralizumab in adults with asthma. |
Wark 2003 | Intervention used in study (itraconazole) is not anti‐IL‐5 therapy |
Weinstein 2016 | Combined secondary analysis of two trials: NCT01287039 and NCT01285323 |
Wenzel 2009 | Intervention used in study (golimumab) is not anti‐IL‐5 therapy |
Wenzel 2013a | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Wenzel 2013b | Interventionused in study (dupilumab) is not anti‐IL‐5 therapy |
Wenzel 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Yan 2015 | Participants do not have a diagnosis of asthma |
Zetterstrom 1972 | Participants do not all have diagnosis of asthma |
Zhu 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Zielen 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
RCT: randomised controlled trial